National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials (PDQ®)
Patient Version   Health Professional Version
First Published: 10/2/2007  
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Maintenance Rituximab for Follicular Lymphoma

Azacitidine Improves Survival in MDS

Second Stem Cell Transplant Not Helpful in Myeloma
Related Links
Educational Materials About Clinical Trials

Clinical Trials: Questions and Answers

Questions to Ask Your Doctor

Drug Information from MedlinePlus
Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase III Randomized Study of Gemcitabine Hydrochloride and Sorafenib Tosylate in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Pancreas

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overOtherIPC-BAYPAN
BAYPAN, INCA-RECF0426, IPC-2005-006, NCT00541021

Trial Description

Purpose:

Drugs used in chemotherapy such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether giving gemcitabine together with sorafenib is more effective than giving gemcitabine alone in treating pancreatic cancer.

This randomized phase III trial is studying giving gemcitabine together with sorafenib to see how well it works compared with giving gemcitabine alone in treating patients with locally advanced or metastatic pancreatic cancer.

Eligibility:

Eligibility criteria include the following:

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will be randomly assigned (have an equal chance of being placed) to one of two treatment groups.

Patients in group one will receive sorafenib by mouth twice a day and an infusion of gemcitabine once a week. Treatment may continue for 7 weeks followed by 1 week of rest during course one. In the next two courses, patients will receive sorafenib twice a day and gemcitabine once a week for 3 weeks followed by 1 week of rest.

Patients in group two will receive a placebo by mouth twice a day and an infusion of gemcitabine once a week. Treatment may continue for 7 weeks followed by 1 week of rest during course one. In the next two courses, patients will receive a placebo twice a day and gemcitabine once a week for 3 weeks followed by 1 week of rest.

After finishing three courses of treatment, patients in both groups may continue to receive sorafenib or a placebo for as long as benefit is shown.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes

Frederic Viret, MD, Study coordinator
Ph: 33-4-91-22-35-37
Email: viretf@marseille.fnclcc.fr

Trial Sites

France
  Marseille
 Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
 Frederic Viret, MD
Ph: 33-4-91-22-35-37
 Email: viretf@marseille.fnclcc.fr

Registry Information
Official Title Phase III randomized, double-blind study comparing gemcitabine and sorafenib or a placebo in patients with locally advanced or metastatic cancer of the pancreas.
Trial Start Date 2006-12-12
Registered in ClinicalTrials.gov NCT00541021
Date Submitted to PDQ 2007-08-20
Information Last Verified 2008-12-28

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov